NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
LANOXIN (digoxin) by Pfizer is digoxin's actions are mediated through its effects on na-k atpase. First approved in 1954.
Drug data last refreshed 16h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANOXIN (digoxin) is a cardiac glycoside administered via injection that increases myocardial contractility and slows heart rate by inhibiting the Na-K ATPase pump, increasing intracellular calcium availability in cardiac tissue. It is primarily indicated for heart failure and atrial fibrillation management. The drug works through positive inotropic action, negative chronotropic effects, and neurohormonal deactivation.
LOE Approaching
This product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature, defensive positioning where brand teams focus on retention and cost management rather than growth.
Mechanism of Action
digoxin's actions are mediated through its effects on Na-K ATPase. This enzyme, the "sodium pump," is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin causes increased availability…
Pharmacologic Class:
Cardiac Glycoside
Indications
Worked on LANOXIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.